SCHEMBL5332289

SCHEMBL5332289

CCCC1CCN(CCCCc2nc3ccccc3o2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 10/20 0.57
DRD2 P14416 8/20 0.57
DRD4 P21917 6/20 0.57
DRD1 P21728 2/20 0.56
HTR1A P08908 3/20 0.53
HTR2A P28223 2/20 0.53
HTR7 P34969 2/20 0.52
HRH1 P35367 2/20 0.52
HTR2B P41595 2/20 0.52
SLC6A4 P31645 1/20 0.52
HRH3 Q9Y5N1 2/20 0.49
NPC1 O15118 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
LOXL2 Q9Y4K0 1/20 0.43
KCNH2 Q12809 2/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5337878 0.97 DRD3 (0.61) DRD3DRD2DRD4DRD1HTR1A
SCHEMBL5332526 0.94 DRD3 (0.56) DRD3DRD2DRD4DRD1HTR1A
SCHEMBL5334375 0.92 DRD3 (0.55) DRD3DRD2DRD4DRD1HTR1A
SCHEMBL5334868 0.91 DRD3 (0.60) DRD3DRD2DRD4DRD1HTR1A
SCHEMBL5336968 0.91 DRD3 (0.59) DRD3DRD2DRD4DRD1HTR1A
SCHEMBL5335030 0.87 DRD3 (0.53) DRD3DRD2DRD4DRD1HTR1A
SCHEMBL5343031 0.87 DRD3 (0.63) DRD3DRD2DRD4DRD1HTR1A
SCHEMBL5335216 0.86 DRD3 (0.61) DRD3DRD2DRD4DRD1HTR1A
SCHEMBL5335844 0.82 DRD3 (0.66) DRD3DRD2DRD4DRD1HTR1A
SCHEMBL5340409 0.82 DRD3 (0.57) DRD3DRD2DRD4DRD1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155795-A1 MUSCARINIC AGONISTS ACADIA PHARMACEUTICALS INC. (US) 2007-07-05 US disclosed
US-7238713-B2 Muscarinic agonists ACADIA PHARMACEUTICALS, INC. (US) 2007-07-03 US disclosed
EP-1535912-A1 Muscarinic agonists Arcadia Pharmaceuticals Inc. (US) 2005-06-01 EP disclosed
US-20050113357-A1 Muscarinic agonists ANDERSON CARL-MAGNUS A (DK) 2005-05-26 US disclosed
US-6627645-B2 Cholinergic agents ACADIA PHARMACEUTICALS, INC. 2003-09-30 US disclosed
US-20020037886-A1 Muscarinic agonists ACADIA PHARMACEUTICALS INC. 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037886-A1 Muscarinic agonists CHRM2, CHRM1, CHRM4 DRD3 682/4885DRD2 476/4885DRD4 544/4885
US-20070155795-A1 MUSCARINIC AGONISTS CHRM2, CHRM1, CHRM4 DRD3 682/4885DRD2 476/4885DRD4 544/4885
US-20050113357-A1 Muscarinic agonists CHRM2, CHRM1, CHRM4 DRD3 682/4885DRD2 476/4885DRD4 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.